Our interest in developing more quantitative and accurate measurements of HER family proteins and pathway activity is based on our previous demonstration of measurable HER2-EGFR protein phosphorylation and downstream pathway activity in HER2− breast tumors in the I-SPY Trial.24 This evidence concerns the gene EGFR and breast neoplasm.